-+ 0.00%
-+ 0.00%
-+ 0.00%

Lyra Therapeutics FY 2024 GAAP EPS $(1.43) Misses $(1.38) Estimate, Sales $1.534M Beat $1.524M Estimate

Benzinga·03/13/2025 20:44:29
Listen to the news
Lyra Therapeutics (NASDAQ:LYRA) reported quarterly losses of $(1.43) per share which missed the analyst consensus estimate of $(1.38) by 3.62 percent. This is a 13.49 percent decrease over losses of $(1.26) per share from the same period last year. The company reported quarterly sales of $1.534 million which beat the analyst consensus estimate of $1.524 million by 0.69 percent. This is a 1.54 percent decrease over sales of $1.558 million the same period last year.